Based on the key indicators related to Capricor Therapeutics' liquidity, profitability, solvency, and operating efficiency, Capricor Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Capricor Therapeutics' Other Stockholder Equity is relatively stable compared to the past year. As of 01/19/2025, Total Liabilities is likely to grow to about 43.6 M, while Non Currrent Assets Other are likely to drop slightly above 234.9 K. Key indicators impacting Capricor Therapeutics' financial strength include:
Investors should never underestimate Capricor Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Capricor Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Capricor Therapeutics.
Net Income
(19.06 Million)
Capricor
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Total Cash From Financing Activities
Begin Period Cash Flow
Other Cashflows From Financing Activities
Stock Based Compensation
Sale Purchase Of Stock
Change To Inventory
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change Receivables
Net Borrowings
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Accounts Payable
Non Current Assets Total
Non Currrent Assets Other
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Common Stock
Net Debt
Cash
Cash And Short Term Investments
Net Receivables
Total Current Assets
Other Current Liab
Short Long Term Debt Total
Short Term Debt
Property Plant And Equipment Net
Other Current Assets
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Intangible Assets
Net Tangible Assets
Other Assets
Long Term Debt
Good Will
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Inventory
Property Plant Equipment
Non Current Liabilities Total
Non Current Liabilities Other
Other Liab
Current Deferred Revenue
Long Term Debt Total
Short Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Tax Expense
Selling And Marketing Expenses
Selling General Administrative
Total Revenue
Gross Profit
Income Before Tax
Total Other Income Expense Net
Research Development
Net Income From Continuing Ops
Cost Of Revenue
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Capricor Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Capricor Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Capricor Therapeutics' assets may result in an increase in income on the income statement.
Capricor Therapeutics competes with Bio Path, NextCure, Pulmatrix, Akari Therapeutics, and Soleno Therapeutics. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. The company was founded in 2005 and is headquartered in San Diego, California. Capricor Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Capricor Therapeutics's current stock value. Our valuation model uses many indicators to compare Capricor Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Capricor Therapeutics competition to find correlations between indicators driving Capricor Therapeutics's intrinsic value. More Info.
Capricor Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Capricor Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Capricor Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Capricor Therapeutics Systematic Risk
Capricor Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Capricor Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Capricor Therapeutics correlated with the market. If Beta is less than 0 Capricor Therapeutics generally moves in the opposite direction as compared to the market. If Capricor Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Capricor Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Capricor Therapeutics is generally in the same direction as the market. If Beta > 1 Capricor Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Capricor Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Capricor Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Capricor Therapeutics growth as a starting point in their analysis.
Capricor Therapeutics January 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Capricor Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Capricor Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Capricor Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Capricor Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Capricor Therapeutics's daily price indicators and compare them against related drivers.
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.